Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is experiencing a notable increase in operating expenses, with FY25 expenses rising by 36% to $468 million compared to FY24, reflecting the company's investment in its therapeutic development pipeline and operational growth. The positive clinical outcomes associated with its lead candidate, z-rostudirsen, including significant improvements in dystrophin expression and cardiopulmonary function, underscore the therapeutic potential and market viability of Dyne’s FORCE platform and its promising pipeline. Moreover, the expected positive readout of a competitor's Phase III trial provides a potential catalyst for Dyne, enhancing the projection for substantial upside movement in the company's shares.

Bears say

Dyne Therapeutics Inc has reported a significant net loss of $446 million for the year, leading to an earnings per share (EPS) of ($3.47), which reflects a deterioration compared to the prior year's loss and EPS figures. Key downside risks include potential failures in clinical trials, particularly the DYNE-101 P1/2 ACHIEVE study, and various delays associated with regulatory pathways that could hinder market entry and overall development of the company’s therapeutics. Furthermore, the company has been trading at a discount relative to its peers, raising concerns regarding its DM1 program timeline and the uncertain outcomes of ongoing clinical studies, which could lead to further downward pressure on the stock.

Dyne Therapeutics (DYN) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 12 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.